AlphaMark Advisors’s Bristol-Myers Squibb BMY Stock Holding History

AlphaMark Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$2.27M	Sell	40,089 -885	-2%	-$49.4K	0.98%	24
2024 Q3	$2.12M	Buy	40,974 +1,708	+4%	+$80.1K	0.73%	26
2024 Q2	$1.63M	Buy	39,266 +16,661	+74%	+$746K	0.57%	33
2024 Q1	$1.23M	Buy	22,605 +514	+2%	+$26.2K	0.43%	40
2023 Q4	$1.13M	Sell	22,091 -1,089	-5%	-$57.2K	0.43%	43
2023 Q3	$1.34M	Buy	23,180 +520	+2%	+$31.9K	0.58%	35
2023 Q2	$1.45M	Sell	22,660 -2,587	-10%	-$173K	0.67%	34
2023 Q1	$1.75M	Buy	25,247 +73	+0.3%	+$5.15K	0.79%	32
2022 Q4	$1.81M	Buy	25,174 +23	+0.1%	+$1.73K	0.91%	28
2022 Q3	$1.79M	Buy	25,151 +397	+2%	+$28.8K	0.89%	29
2022 Q2	$1.91M	Buy	24,754 +60	+0.2%	+$4.57K	0.88%	27
2022 Q1	$1.8M	Sell	24,694 -126	-0.5%	-$8.46K	0.67%	37
2021 Q4	$1.55M	Sell	24,820 -826	-3%	-$48.5K	0.54%	42
2021 Q3	$1.52M	Buy	25,646 +245	+1%	+$16.1K	0.55%	45
2021 Q2	$1.7M	Buy	25,401 +135	+0.5%	+$8.8K	0.62%	41
2021 Q1	$1.59M	Sell	25,266 -2,651	-9%	-$165K	0.61%	39
2020 Q4	$1.73M	Sell	27,917 -18,777	-40%	-$1.15M	0.66%	38
2020 Q3	$2.81M	Buy	46,694 +3,038	+7%	+$183K	1.17%	27
2020 Q2	$2.57M	Buy	43,656 +315	+0.7%	+$18.8K	1.11%	33
2020 Q1	$2.42M	Sell	43,341 -298	-0.7%	-$18.2K	1.34%	29
2019 Q4	$2.8M	Buy	43,639 +43,389	+17,356%	+$2.48M	1.17%	34
2019 Q3	$13K	Hold	250	–	–	0.01%	300
2019 Q2	$11K	Hold	250	–	–	﹤0.01%	316
2019 Q1	$12K	Hold	250	–	–	0.01%	308
2018 Q4	$13K	Hold	250	–	–	0.01%	288
2018 Q3	$16K	Sell	250 -300	-55%	-$17.8K	0.01%	307
2018 Q2	$30K	Sell	550 -250	-31%	-$13.5K	0.01%	262
2018 Q1	$51K	Hold	800	–	–	0.02%	202
2017 Q4	$49K	Sell	800 -100	-11%	-$6.25K	0.02%	206
2017 Q3	$57K	Hold	900	–	–	0.02%	178
2017 Q2	$50K	Hold	900	–	–	0.02%	193
2017 Q1	$49K	Hold	900	–	–	0.02%	188
2016 Q4	$53K	Hold	900	–	–	0.03%	164
2016 Q3	$49K	Hold	900	–	–	0.02%	143
2016 Q2	$66K	Sell	900 -150	-14%	-$10.6K	0.04%	125
2016 Q1	$67K	Hold	1,050	–	–	0.04%	120
2015 Q4	$72K	Hold	1,050	–	–	0.04%	119
2015 Q3	$62K	Sell	1,050 -200	-16%	-$12.7K	0.03%	123
2015 Q2	$83K	Hold	1,250	–	–	0.05%	117
2015 Q1	$81K	Hold	1,250	–	–	0.05%	121
2014 Q4	$74K	Hold	1,250	–	–	0.05%	130
2014 Q3	$64K	Hold	1,250	–	–	0.04%	135
2014 Q2	$61K	Buy	1,250 +250	+25%	+$12.3K	0.04%	141
2014 Q1	$52K	Hold	1,000	–	–	0.03%	144
2013 Q4	$53K	Hold	1,000	–	–	0.03%	144
2013 Q3	$46K	Sell	1,000 -200	-17%	-$8.78K	0.03%	154
2013 Q2	$54K	Buy	+1,200	New	+$52.1K	0.03%	159

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AlphaMark Advisors's BMY Position: Q4 2024 in Review

AlphaMark Advisors reduced its Bristol-Myers Squibb (BMY) stake by 2.2% in Q4 2024, selling an estimated $49.4K and leaving 40,089 shares worth $2.27M. The position accounts for 0.98% of the portfolio, ranked #24.

AlphaMark Advisors first reported a position in BMY in Q2 2013 and has held it in 47 quarters since. The position peaked at $2.81M in Q3 2020. 2,487 funds tracked by Wall St. Rank hold BMY as of Q4 2024.

AlphaMark Advisors held 40,089 shares of Bristol-Myers Squibb worth $2.27M as of Q4 2024.
AlphaMark Advisors sold 885 Bristol-Myers Squibb shares in Q4 2024, an estimated $49.4K.
Bristol-Myers Squibb made up 0.98% of AlphaMark Advisors's portfolio in Q4 2024, its #24 holding.
AlphaMark Advisors first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 47 quarters since.
AlphaMark Advisors's Bristol-Myers Squibb position peaked at $2.81M in Q3 2020.
2,487 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2024.

Based on AlphaMark Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.